TBX2 driven switch from Androgen Receptor to Glucocorticoid Receptor signaling confers therapeutic resistance in Prostate Cancer
S. Dutta, G. K. Patel, H. Khedmatgozar, D. Latour, M. Tripathi, S. Nandana
This study identifies TBX2 as a molecular switch that represses AR and activates GR signaling, driving enzalutamide resistance in CRPC, and suggests SP2509 as a potential therapeutic strategy.
bioRxiv · May 7, 2023Cancer Biology